CJC-1295 (No DAC)

CJC-1295 (No DAC)

CJC-1295 (No DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH), engineered for enhanced stability and receptor affinity compared to the native peptide. Unlike the DAC (Drug Affinity Complex) variant, CJC-1295 without DAC has a shorter half-life, producing pulsatile growth hormone release that more closely mimics endogenous GH secretion patterns. It is widely used in preclinical research investigating the GH/IGF-1 axis, pituitary function, and anabolic signalling.

Mechanism of Action

CJC-1295 (No DAC) binds to and activates the GHRH receptor (GHRHR) on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. This in turn drives hepatic IGF-1 production, which mediates downstream anabolic and metabolic effects including protein synthesis, lipolysis, and cellular proliferation. The peptide incorporates amino acid substitutions that confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, extending its activity relative to native GHRH(1-29).

Research Applications

• GH/IGF-1 axis and pituitary somatotroph function studies
• Pulsatile growth hormone secretion modelling
• Anabolic signalling and protein synthesis research
• Body composition and metabolic regulation investigation
• GHRH receptor pharmacology studies

Specifications

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• CAS Number: 863288-34-0
• Purity: ≥98%
• Molecular Weight: 3367.9 g/mol
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.